Status:
UNKNOWN
ASIA Study : French Register of Inflammatory Eye Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Patients Treated for Cancer by Immunotherapy
Eligibility:
All Genders
18+ years
Brief Summary
New anticancer therapies based on lifting the inhibition of the immunological synapse are used in the therapeutic arsenal of a growing number of neoplasias (melanoma, lung cancer, hepatocellular carci...
Eligibility Criteria
Inclusion
- age\> 18
- under cancer immunotherapy: anti-PD1 (nivolumab, pembrolizumab), anti-CTLA4 (ipilimumab), anti-PDL1 (atezolizumab, durvalumab, avelumab)
- diagnosis of uveitis / inflammatory ophthalmologic disease confirmed by at least an ophthalmologist
- indicating his/her non-opposition to participating in the study
Exclusion
- NA
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04760197
Start Date
April 1 2019
End Date
December 1 2021
Last Update
February 18 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers - Service de Médecine Interne - Immunologie Clinique
Angers, France, 49933
2
Hôpital de la Croix-Rousse - Service de médecine interne - 103 Grande Rue de la Croix-Rousse
Lyon, France, 69004